静脉铁剂市场、机会、成长动力、产业趋势分析与预测，2024-2032

2023 年，全球静脉 (IV) 铁剂药物市场估值约为 17 亿美元，预计 2024 年至 2032 年复合年增长率为 6.7%。治疗或预防不能有效吸收口服铁补充剂或需要快速补充铁的患者的缺铁性贫血。

慢性肾臟病（CKD）、癌症和发炎性疾病等慢性病的盛行率不断上升推动了市场的成长。这些健康问题通常会导致贫血，增加了对静脉铁剂疗法的需求，以恢復铁水平并改善患者的预后。促进市场扩张的其他因素包括缺铁诊断意识的提高、人口老化以及静脉注射铁剂药物配方的不断进步。

整个静脉注射 (IV) 铁剂药物行业根据药物类型、应用、配销通路和地区进行分类。

IV铁药物市场按药物类型细分，包括右旋糖酐铁、蔗糖铁和羧基麦芽糖铁。其中，羧基麦芽糖铁部分预计到2032 年将达到15 亿美元。的首选患者和医疗保健提供者。

从应用来看，市场分为CKD、发炎性肠道疾病和癌症等细分市场。 CKD 细分市场到 2023 年将达到 10 亿美元，预计将继续占据主导地位。 CKD 患者经常难以胃肠道吸收铁，这使得静脉铁剂成为更有效的治疗选择。此外，静脉注射铁有助于提高血红蛋白水平并刺激红血球生成，这对于控制 CKD 患者的贫血至关重要。

静脉配销通路的通路分为医院药局、零售药局和网路药局。医院药局部门预计到 2032 年将达到 14 亿美元，受益于其在静脉注射疗法管理、副作用监测和确保药物製剂严格品质控制方面的专业知识。

美国市场预计将大幅成长，到 2032 年将达到 10 亿美元。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性病盛行率上升
    • 提高及时诊断铁缺乏症的意识
    • 老年人口不断增加
    • 静脉注射铁剂药物配方的进展
  • 产业陷阱与挑战
    • 静脉注射补铁药物相关的高成本
    • 不良反应和安全问题
• 成长潜力分析
• 监管环境
• 管道分析
• 2023 年定价分析
  • 按地区
  • 按关键人物
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032 年

• 主要趋势
• 右旋糖酐铁
• 蔗糖铁
• 羧基麦芽糖铁
• 其他药物类型

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 慢性肾臟病
• 发炎性肠道疾病
• 癌症
• 其他应用

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AbbVie Inc.
• AdvaCare Pharma
• Akebia Therapeutics, Inc.
• AMAG Pharmaceuticals. Inc.
• Bayer AG
• Covis Pharma GmbH
• CSL Limited
• Daiichi Sankyo Company, Ltd.
• F. Hoffmann-La Roche Ltd.
• Fresenius SE and Co. KGaA
• Novartis AG
• PHARMACOSMOS A/S
• Rockwell Medical, Inc.
• Sanofi
• Zydus Lifesciences Limited

The Global Intravenous (IV) Iron Drugs Market was valued at approximately USD 1.7 billion in 2023 and is expected to grow at a CAGR of 6.7% from 2024 to 2032. IV iron drugs are specialized formulations of iron administered directly into the bloodstream, commonly used for treating or preventing iron deficiency anemia in patients who cannot effectively absorb oral iron supplements or require rapid iron replenishment.

The market growth is driven by the increasing prevalence of chronic conditions such as chronic kidney disease (CKD), cancer, and inflammatory disorders. These health issues often result in anemia, heightening the need for IV iron therapies to restore iron levels and improve patient outcomes. Additional factors contributing to market expansion include rising awareness of iron deficiency diagnosis, an aging population, and ongoing advancements in IV iron drug formulations.

The overall intravenous (IV) iron drugs industry is segregated based on Drug Type, Application, Distribution Channel, and Region.

The IV iron drugs market is segmented by drug type, including iron dextran, iron sucrose, and ferric carboxymaltose. Among these, the ferric carboxymaltose segment is projected to reach USD 1.5 billion by 2032. This drug offers several benefits, such as high elemental iron concentration, fewer infusions, quicker administration times, and a favorable safety profile, making it a preferred choice for many patients and healthcare providers.

In terms of application, the market is divided into segments like CKD, inflammatory bowel disease, and cancer. The CKD segment accounted for USD 1 billion in 2023 and is expected to remain dominant. CKD patients often struggle with gastrointestinal absorption of iron, making IV iron a more efficient treatment option. Additionally, IV iron helps to increase hemoglobin levels and stimulate red blood cell production, which is crucial for managing anemia in CKD patients.

The distribution channel for IV iron drugs is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment is projected to reach USD 1.4 billion by 2032, benefiting from their expertise in administering IV therapies, monitoring for side effects, and ensuring stringent quality control in drug preparation.

The U.S. market is expected to grow significantly, reaching USD 1 billion by 2032. Factors such as a robust healthcare infrastructure and the rising prevalence of chronic conditions contribute to the increasing demand for IV iron drugs in the country.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic diseases
    • 3.2.1.2 Increasing awareness towards timely diagnosis of iron deficiencies
    • 3.2.1.3 Growing geriatric population
    • 3.2.1.4 Advancements in intravenous iron drug formulations
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with intravenous iron drugs
    • 3.2.2.2 Adverse reactions and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Iron dextran
• 5.3 Iron sucrose
• 5.4 Ferric carboxymaltose
• 5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Chronic kidney disease
• 6.3 Inflammatory bowel disease
• 6.4 Cancer
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 AdvaCare Pharma
• 9.3 Akebia Therapeutics, Inc.
• 9.4 AMAG Pharmaceuticals. Inc.
• 9.5 Bayer AG
• 9.6 Covis Pharma GmbH
• 9.7 CSL Limited
• 9.8 Daiichi Sankyo Company, Ltd.
• 9.9 F. Hoffmann-La Roche Ltd.
• 9.10 Fresenius SE and Co. KGaA
• 9.11 Novartis AG
• 9.12 PHARMACOSMOS A/S
• 9.13 Rockwell Medical, Inc.
• 9.14 Sanofi
• 9.15 Zydus Lifesciences Limited